Clinical trials: Schizophrenia
Perceptual Disorders, Confusion
Ketamine Challenge Study With JNJ-40411813
The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine.
- Conditions
- Perceptual Disorders, Confusion, Schizophrenia
- Trial name
- NCT01101659
- Testing
- JNJ-40411813, normal saline, ketamine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Fast Titration in the Treatment of Schizophrenia, Taiwan
Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.
- Trial name
- NCT00304473
- Testing
- Quetiapine fumarate
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Schizophrenia
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters.
- Trial name
- NCT05563818
- Testing
- WinterLight Mobile Phone Speech Analysis
- Where
- 4 sites in Algeria, Egypt and 2 more
- Volunteers
- 57 people
- Sponsor
- Hikma Pharmaceuticals LLC
Cognitive Deficits in Schizophrenia
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01095562
- Testing
- ABT-126
- Where
- 23 sites in United States
- Volunteers
- 207 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
- Trial name
- NCT00193713
- Testing
- bifeprunox
- Sponsor
- Solvay Pharmaceuticals
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
- Trial name
- NCT07101094
- Testing
- xanomeline and trospium chloride (X/T) therapy
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Brexpiprazole in Patients With Acute Schizophrenia
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
- Trial name
- NCT01810380
- Testing
- Brexpiprazole, Quetiapine extended release
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- H. Lundbeck A/S
Acute Agitation
A Study of Olanzapine in Patients With Acute Agitation
The purpose of this study is to assess the efficacy and safety of intramuscular olanzapine for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
- Trial name
- NCT05803642
- Testing
- Olanzapine, Haloperidol
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq.
- Trial name
- NCT00590577
- Testing
- Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Paliperidone palmitate 100 mg eq.
- Where
- 66 sites in United States, Malaysia and 6 more
- Volunteers
- 652 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with…
- Trial name
- PRE-COG (NCT00358852)
- Testing
- No intervention
- Volunteers
- 2,339 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Acute Episode
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control.
- Trial name
- NCT03055338
- Testing
- Elpipodect, Risperidone
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and…
- Trial name
- NCT02002832
- Testing
- Lurasidone tablets, Risperidone tablets
- Where
- 15 sites in China
- Volunteers
- 388 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.